ESPERION THERAPEUTICS INC (ESPR) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:ESPR • US29664W1053

3.39 USD
-0.16 (-4.51%)
At close: Jan 30, 2026
3.3901 USD
0 (0%)
After Hours: 1/30/2026, 8:00:02 PM

ESPR Key Statistics, Chart & Performance

Key Statistics
Market Cap810.41M
Revenue(TTM)303.80M
Net Income(TTM)-105.83M
Shares239.06M
Float235.80M
52 Week High4.18
52 Week Low0.69
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.5
PEN/A
Fwd PE50.26
Earnings (Next)02-24
IPO2013-06-24
Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
ESPR short term performance overview.The bars show the price performance of ESPR in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100

ESPR long term performance overview.The bars show the price performance of ESPR in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 20 -20 40 -40 60 80

The current stock price of ESPR is 3.39 USD. In the past month the price decreased by -8.38%. In the past year, price increased by 89.39%.

ESPERION THERAPEUTICS INC / ESPR Daily stock chart

ESPR Technical Analysis

ChartMill assigns a technical rating of 6 / 10 to ESPR. When comparing the yearly performance of all stocks, ESPR is one of the better performing stocks in the market, outperforming 93.35% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

ESPR Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ESPR. ESPR may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ESPR Financial Highlights

Over the last trailing twelve months ESPR reported a non-GAAP Earnings per Share(EPS) of -0.5. The EPS increased by 21.87% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -29.07%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-6.67%
Sales Q2Q%69.1%
EPS 1Y (TTM)21.87%
Revenue 1Y (TTM)2.83%

ESPR Forecast & Estimates

14 analysts have analysed ESPR and the average price target is 6.59 USD. This implies a price increase of 94.52% is expected in the next year compared to the current price of 3.39.

For the next year, analysts expect an EPS growth of 81.8% and a revenue growth 27.9% for ESPR


Analysts
Analysts78.57
Price Target6.59 (94.4%)
EPS Next Y81.8%
Revenue Next Year27.9%

ESPR Ownership

Ownership
Inst Owners46.36%
Ins Owners0.49%
Short Float %14.39%
Short Ratio5.4

About ESPR

Company Profile

ESPR logo image Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.

Company Info

ESPERION THERAPEUTICS INC

3891 Ranchero Drive, Suite 150, Suite 300

Ann Arbor MICHIGAN 48108 US

CEO: Tim M. Mayleben

Employees: 304

ESPR Company Website

ESPR Investor Relations

Phone: 17348873903

ESPERION THERAPEUTICS INC / ESPR FAQ

What does ESPERION THERAPEUTICS INC do?

Esperion Therapeutics, Inc. is a pharmaceutical company, which engages in the development and commercialization of oral therapies for elevated low-density lipoprotein cholesterol. The company is headquartered in Ann Arbor, Michigan and currently employs 304 full-time employees. The company went IPO on 2013-06-24. The firm is focused on developing and commercializing oral, once-daily, non-statin medicines for patients who are at risk for cardiovascular disease (CVD) and are struggling with elevated low-density lipoprotein cholesterol (LDL-C). Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. Its NEXLETOL and NEXLIZET (bempedoic acid and ezetimibe) tablets are oral, once-daily, non-statin medicines to lower the risk of myocardial infarction and coronary revascularization in adults with primary hyperlipidemia. Its NEXLETOL is an ATP Citrate Lyase (ACLY), inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors. Its NUSTENDI contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and absorption in the intestine.


What is the current price of ESPR stock?

The current stock price of ESPR is 3.39 USD. The price decreased by -4.51% in the last trading session.


What is the dividend status of ESPERION THERAPEUTICS INC?

ESPR does not pay a dividend.


What is the ChartMill technical and fundamental rating of ESPR stock?

ESPR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Which stock exchange lists ESPR stock?

ESPR stock is listed on the Nasdaq exchange.


Can you provide the sector and industry classification for ESPERION THERAPEUTICS INC?

ESPERION THERAPEUTICS INC (ESPR) operates in the Health Care sector and the Pharmaceuticals industry.